IFM Therapeutics
Boston
About IFM Therapeutics
IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of the cGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $82.5M
- Funding stage: M&A
- Last round: Series Unknown (Dec 2019)
- Website: ifmthera.com
- Phone: +1-857-327-9903
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ifm-therapeutics-70955 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.